Cervical cancer is the fourth most common malignancy in women worldwide. However, screening with human papillomavirus (HPV) molecular tests holds promise for reducing cervical cancer incidence and mortality in low- and middle-income countries. The performance of the Abbott RealTime High-Risk HPV test (AbRT) was evaluated in 83 cervical smear specimens and compared with a conventional nested PCR coupled to high-throughput sequencing (HTS) to identify the amplicons.
The AbRT assay detected at least one HPV genotype in 44.57% of women regardless of the grade of cervical abnormalities. Except for one case, good concordance was observed for the genotypes detected with the AbRT assay in the high-risk HPV category determined with HTS of the amplicon generated by conventional nested PCR.
The AbRT test is an easy and reliable molecular tool and was as sensitive as conventional nested PCR in cervical smear specimens for detection HPVs associated with high-grade lesions. Moreover, sequencing amplicons using an HTS approach effectively identified the genotype of the hrHPV identified with the AbRT test.
Bruni L. B-RL, Albero G., Aldea M., Serrano B., Valencia S., Brotons M., Mena M., Cosano R., Munoz J., Bosch FX., de Sanjosé S., Castellsagué X., ICO Information Centre on HPV and Cancer (HPV Information Centre): Human Papillomavirus and Related Diseases in the World. Summary Report 2014:12-18.
Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, Demuth F, Schiffman M, Wacholder S, Castle PE. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12(7):663–72. CrossRefPubMedPubMedCentral
Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, Voorhorst FJ, Verheijen RH, van Groningen K, Boon ME, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370(9601):1764–72. CrossRefPubMed
Cubie HA, Cuschieri K. Understanding HPV tests and their appropriate applications. Cytopathology. 2013;24(5):289–308. PubMed
Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch FX, Cuzick J, Dillner J, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009;124(3):516–20. CrossRefPubMedPubMedCentral
Santesso N, Mustafa RA, Schunemann HJ, Arbyn M, Blumenthal PD, Cain J, Chirenje M, Denny L, De Vuyst H, Eckert LO, et al. World Health Organization guidelines for treatment of cervical intraepithelial neoplasia 2-3 and screen-and-treat strategies to prevent cervical cancer. Int J Gynaecol Obstet. 2016;132(3):252–8. CrossRefPubMed
Moussavou PB, Koumakpayi IH, Nkili-Meyong AA, Labouba I, Bisvigou U, Chansi JK, Engohan-Aloghe C, Dissanami F, Ambounda N, Delannoy-Vieillard AS, et al. Molecular analysis of human Papillomavirus detected among women positive for cervical lesions by visual inspection with acetic acid/Lugol's iodine (VIA/VILI) in Libreville, Gabon. Infect Agent Cancer. 2016;11(1):50. CrossRefPubMedPubMedCentral
de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen virology. 1995;76(Pt 4):1057–62. CrossRef
Remmerbach TW, Brinckmann UG, Hemprich A, Chekol M, Kuhndel K, Liebert UG. PCR detection of human papillomavirus of the mucosa: comparison between MY09/11 and GP5+/6+ primer sets. J Clinical Virol. 2004;30(4):302–8. CrossRef
Kocjan BJ, Maver PJ, Hosnjak L, Zidar N, Odar K, Gale N, Poljak M. Comparative evaluation of the Abbott RealTime high risk HPV test and INNO-LiPA HPV genotyping extra test for detecting and identifying human papillomaviruses in archival tissue specimens of head and neck cancers. Acta Dermatovenerol Alp Pannonica Adriat. 2012;21(4):73–5. PubMed
Poljak M, Ostrbenk A, Seme K, Sterbenc A, Jancar N, Vrtacnik Bokal E. Three-year longitudinal data on the clinical performance of the Abbott RealTime high risk HPV test in a cervical cancer screening setting. J Clin Virol. 2015;
Salipante SJ, Sengupta DJ, Rosenthal C, Costa G, Spangler J, Sims EH, Jacobs MA, Miller SI, Hoogestraat DR, Cookson BT, et al. Rapid 16S rRNA next-generation sequencing of polymicrobial clinical samples for diagnosis of complex bacterial infections. PLoS One. 2013;8(5):e65226. CrossRefPubMedPubMedCentral
Tota JE, Ramanakumar AV, Villa LL, Richardson H, Burchell AN, Koushik A, Mayrand MH, Coutlee F, Franco EL. Evaluation of human papillomavirus type replacement postvaccination must account for diagnostic artifacts: masking of HPV52 by HPV16 in anogenital specimens. Cancer Epidemiol Biomark Prev. 2015;24(1):286–90. CrossRef
Cuzick J, Mayrand MH, Ronco G, Snijders P, Wardle J. Chapter 10: new dimensions in cervical cancer screening. Vaccine. 2006;24(Suppl 3):S3/90–7.
Chung HS, Hahm C, Lee M. Comparison of the clinical performances of the AdvanSure HPV screening real-time PCR, the Abbott real-time high-risk HPV test, and the hybrid capture high-risk HPV DNA test for cervical cancer screening. J Virol Methods. 2014;205C:57–60. CrossRef
Hesselink AT, Meijer CJ, Poljak M, Berkhof J, van Kemenade FJ, van der Salm ML, Bogaarts M, Snijders PJ, Heideman DA. Clinical validation of the Abbott RealTime high risk HPV assay according to the guidelines for human papillomavirus DNA test requirements for cervical screening. J Clin Microbiol. 2013;51(7):2409–10. CrossRefPubMedPubMedCentral
- Human papillomavirus detection using the Abbott RealTime high-risk HPV tests compared with conventional nested PCR coupled to high-throughput sequencing of amplification products in cervical smear specimens from a Gabonese female population
Ismaël Hervé Koumakpayi
Eric M. Leroy
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II